Key result
FilterWire embolic protection achieves high deployment success with a ~7% MACE rate in SVG stenting.
Why the study?
Saphenous vein graft intervention is associated with significant MACE related to distal vessel embolization, and the FilterWire device was recently approved as an adjunct to SVG intervention.
Does the FilterWire distal embolic protection device improve outcomes and reduce complications in patients undergoing saphenous vein graft stenting?
Observational (n=30)
No
Does the FilterWire distal embolic protection device improve outcomes and reduce complications in patients undergoing saphenous vein graft stenting?
Initial single-center experience demonstrates that the FilterWire distal embolic protection device can be successfully deployed during SVG stenting with a low MACE rate.
High success and low MACE with FilterWire in SVG stenting; supports feasibility but leaves open clinical benefit versus unprotected PCI.
BACKGROUND: Saphenous vein graft (SVG) intervention is associated with a significant incidence of major adverse cardiac events (MACE) related to distal vessel embolization. The FilterWire distal embolic protection device has recently been approved as an adjunct to SVG intervention. We report here our initial experience in a single center in 30 consecutive patients using this device in SVG stenting. HYPOTHESIS: This study examined the outcomes and complications associated with these devices, as well as whether proficiency with the devices increased with greater experience and whether there were measurable outcome differences between devices. METHODS: We retrospectively identified all patients in whom a FilterWire device was placed at our hospital between June 2001 and June 2004. RESULTS: The device was successfully deployed in 29 of 30 patients, and all patients were stented successfully. Overall MACE rate was 6.6%, consistent with reports in larger multicenter clinical trials. Transient decreases in flow were noted while the device was in place in six patients, but improved in five patients with device removal. CONCLUSIONS: This early experience in a single center using FilterWire embolic protection indicates that excellent clinical results can be obtained by the adoption of filter protection for SVG intervention, without evidence for a detrimental learning curve.
No takes yet. Share an insight, caveat, or question.
Kolansky et al. (2005) conducted an observational in Saphenous vein graft (SVG) intervention (n=30). FilterWire distal embolic protection device was evaluated on Major adverse cardiac events (MACE). The FilterWire distal embolic protection device was successfully deployed in 29 of 30 patients undergoing saphenous vein graft stenting, with an overall MACE rate of 6.6%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: